Graftys entered into a distribution agreement whereby OrthoPediatrics will market Graftys® QuickSet bone cement in the U.S. under the tradename QuickPack™.
QuickSet is a new generation macroporous calcium phosphate cement designed with an optimal natural cellular resorption/substitution cycle with a calcium-deficient apatite matrix that is structurally and chemically similar to native bone crystals. QuickSet employs a full range of micro- and macropores and compressive strength in the range of cancellous bone.
Graftys QuickSet/QuickPack is delivered in a closed loop double-compartment syringe specifically designed for safety, reproducibility and ease-of-use, with no risk of preparation mistake and no product loss.
Enrico Bastianelli, Chief Executive Officer of Graftys, said, “By choosing us, OrthoPediatrics offers to our products a wider and focused access to the U.S. territory. This new partnership reinforces our desire to continue to respond to the clinical issues faced daily by orthopedic surgeons.”
Graftys entered into a distribution agreement whereby OrthoPediatrics will market Graftys® QuickSet bone cement in the U.S. under the tradename QuickPack™.
Graftys entered into a distribution agreement whereby OrthoPediatrics will market Graftys® QuickSet bone cement in the U.S. under the tradename QuickPack™.
QuickSet is a new generation macroporous calcium phosphate cement designed with an optimal natural cellular resorption/substitution cycle with a calcium-deficient apatite matrix that is structurally and chemically similar to native bone crystals. QuickSet employs a full range of micro- and macropores and compressive strength in the range of cancellous bone.
Graftys QuickSet/QuickPack is delivered in a closed loop double-compartment syringe specifically designed for safety, reproducibility and ease-of-use, with no risk of preparation mistake and no product loss.
Enrico Bastianelli, Chief Executive Officer of Graftys, said, “By choosing us, OrthoPediatrics offers to our products a wider and focused access to the U.S. territory. This new partnership reinforces our desire to continue to respond to the clinical issues faced daily by orthopedic surgeons.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
